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Overall survivalPurpose: The aim of this study was to evaluate which clinical and treatment-related factors are associated
with heart and lung toxicity in oesophageal cancer patients treated with chemoradiation (CRT). The sec-
ondary objective was to analyse whether these toxicities are associated with overall survival (OS).
Materials and methods: The study population consisted of a retrospective cohort of 216 oesophageal can-
cer patients treated with curative CRT. Clinical and treatment related factors were analysed for OS and
new pulmonary and cardiac events by multivariable regression analyses. The effect of these toxicities
on OS was assessed by Kaplan Meyer analyses.
Results: Multivariable analysis revealed that pulmonary toxicity was best predicted by the mean lung
dose. Cardiac complications were diverse; the most frequently occurring complication was pericardial
effusion. Several cardiac dose parameters correlated with this endpoint. Patients developing radiation
pneumonitis had significantly worse OS than patients without radiation pneumonitis, while no difference
was observed in OS between patients with and without pericardial effusion. OS was best predicted by the
V45 of the lung and tumour stage. None of the cardiac dose parameters predicted OS in multivariable
analyses.
Conclusion: Cardiac dose volume parameters predicted the risk of pericardial effusion and pulmonary
dose volume parameters predicted the risk of radiation pneumonitis. However, in this patient cohort, pul-
monary DVH parameters (V45) were more important for OS than cardiac DVH parameters. These results
suggest that reducing the cardiac dose at the expense of the dose to the lungs might not always be a good
strategy in oesophageal cancer patients.
 2020 The Author(s). Published by Elsevier B.V. Radiotherapy and Oncology 149 (2020) 222–227 This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Over the last decade, increasing numbers of oesophageal cancer
patients have been treated with radiotherapy, either in the neo-
adjuvant setting followed by surgery or as definitive treatment.
Due to neo-adjuvant CRT, cure rates have improved [1,2]. As a con-
sequence, the number of oesophageal cancer survivors at risk of
developing late toxicity is has risen correspondingly.
Traditionally, radiotherapy planning for these patients has
aimed at adequate target coverage while focussing on dose limita-
tion for the spinal cord and lungs in order to prevent radiation-
induced toxicities. In recent years, there has been an increasing
awareness of radiation-induced cardiac toxicity. In breast cancerpatients, prediction models for cardiac toxicity [3,4] indicate a lin-
ear increase of the risk of major coronary events by 7.4% per Gray.
However, in the radiotherapy treatment of oesophageal cancer
the radiation dose to the heart is generally much higher and oeso-
phageal cancer patients generally have less favourable cardiovas-
cular risk profiles. Therefore, prediction models describing the
relationship between dose parameters and cardiac events devel-
oped in breast cancer patients cannot be automatically extrapo-
lated to oesophageal cancer patients.
Limited data currently exists for radiation-induced cardiac tox-
icity in oesophageal cancer patients. Grade III cardiac toxicities are
observed in about 10 percent of these cases and occur relatively
early after treatment. Numerous dose volume parameters of the
heart are significantly associated with a variety of cardiac toxicity
endpoints. However, multivariable prediction models for cardiac
toxicity are not available and it remains unclear which threshold
dose levels should be used in routine clinical practice [5–9]. Never-
theless, in some studies, including of patients with lung and
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cardiac dose and OS, suggesting that cardiac toxicity is a relevant
and possibly underestimated problem in the treatment of these
patients [10–16].
Even with modern photon techniques, such as IMRT and VMAT,
attempts to reduce cardiac dose is generally accompanied by
higher dose levels to the lungs, thus increasing the risk of pul-
monary toxicity. The optimal balance between cardiac and pul-
monary toxicity and its influence on overall survival remains to
be determined.
The main objective of this study was therefore to evaluate
which clinical and treatment-related factors are associated with
cardiac and/or lung toxicity in oesophageal cancer patients after
definitive CRT. The secondary objective was to determine whether
these toxicities are associated with OS.Methods and materials
The study population of this retrospective cohort study con-
sisted of 216 oesophageal cancer patients who had been referred
to the department of radiation oncology in Osaka for definitive
CRT from January 2007 to December 2013. All patients had histo-
logically confirmed carcinoma of the oesophagus and were staged
using CT scans of the neck, chest and abdomen and endoscopic
evaluation. When local treatment was considered, endoscopic
ultrasound was performed. Based on these findings, patients were
restaged according to the 7th edition of the AJCC cancer staging
manual [17].
Target volume delineation was performed on a 3D planning CT
scan. The clinical target volume (CTV) consisted of the primary
tumour and suspicious lymph nodes with a 2–3 cm margin in
cranio-caudal direction along the oesophagus and 5–10 mm mar-
gin in the transversal plane. An additional margin of 5–10 mm
was taken from CTV to PTV in all directions. For T2 and T3 tumours
and in the case of positive lymph nodes, an area of elective nodal
irradiation was delineated depending on the location of the
tumour. For all these patients, the mediastinum was treated to a
total dose of 40 Gy. For upper and middle thoracic tumours, the
supraclavicular region was included in the elective nodal area as
well. For the middle and distal tumours, the truncal region was
included in the target volume and in some cases, elective nodal
irradiation was omitted based on poor clinical condition or very
poor prognostic factors.
For each patient, the whole heart (WH) and its substructures,
including the right and left atria (RA and LA, resp.) and right and
left ventricles (RV and LV, resp.) were contoured using an auto-
matic delineation tool based on the atlas by Feng et al. [18]. Since
the pericardium cannot be identified on CT images, we used a sur-
rogate pericardium (PC), by creating a 3D structure with the WH
contour as inner border and the WH + 5 mm as outer border. The
lungs were delineated and considered as one organ.
Treatment was given on a daily basis, using 10 MV photons in
1.8–2.0 Gy daily fractions to a total dose of 50.4–66.0 Gy (median
dose: 60 Gy). All patients were treated with 3D-conformal radio-
therapy (3D-CRT). In 205 out of 216 patients, radiotherapy was
combined with chemotherapy which mostly consisted of 5-FU
infusions combined with cisplatin. In case of renal dysfunction or
poor performance status a combination of 5-FU with nedaplatin
(8) or docetaxel (14) was administered. Only few patients received
neo-adjuvant (9) and/or adjuvant (7) chemotherapy as well.
All patients were subjected to a follow up program consisting of
follow up visits every 3–6 months for the first 2 years and every
6 months thereafter. Each visit included a physical test, blood test,
oesophageal endoscopy and CT scan of the neck, chest and
abdomen. Hospital charts of all patients were reviewed for theoccurrence of complications and tumour status. Late toxicities
were assessed in accordance with the Common Terminology
Criteria for Adverse Events version 4.0.
The dose distributions were recovered from the treatment plan-
ning system. Dose-volume parameters including doses to whole
heart, substructures of the heart and lungs in 5% bins and mean
doses were imported in the database.
The clinical endpoints were newly diagnosed cardiac and pul-
monary events and overall survival. Dose-volume histogram
(DVH) parameters, treatment and patient-related parameters as
mentioned in Tables 1 and 2 were included as potential risk fac-
tors. Cardiac events were analysed as a composed endpoint for
all cardiac events as listed in Table 3, but also separately as their
aetiologies may be different. Tumour-related parameters, like
stage, N-status and elective irradiation, were not taken into
account in the logistic regression analyses because of their correla-
tion with DVH parameters. However, for OS these known prognos-
tic factors for OS were included in the multivariable Cox regression
analysis.
To analyse possible associations of clinical and treatment-
related factors with cardiac and lung toxicity, univariable logistic
regression analysis was performed, using a cut-off level of p-
value <0.2. The selected parameters were tested for multicollinear-
ity using an R-square threshold >0.8. Clinical factors were excluded
in case of a high number of missing data and in case the number of
equivalent cases in one group was smaller than 10% (Table 2).
The remaining clinical and dosimetric parameters were
included in a multivariable forward stepwise logistic regression
analysis based on largest significant log-likelihood differences,
which was performed in SPSS. Variables were added to the final
model when the model significantly improved (p < 0.05) based
on the likelihood ratio test. For the OS analyses a forward stepwise
multivariable cox regression was used based on the log-likelihood.
To test the internal validity, the entire variable selection for both
the toxicities and survival was repeated in 1000 bootstrap samples
(i.e. with replacement). The selected model optimism was evalu-
ated by calculating the difference between the performance of
the models in each bootstrap and in the original sample, according
to the TRIPOD statement.[19] Both the area, and the adjusted area
under de ROC curves are presented in order to quantify the predic-
tive power of the analyses.
Finally, the effect of the toxicities on OS was analysed using
Kaplan Meier analyses.Results
All new cardiopulmonary complications during follow up are
summarized in Table 3. Radiological changes in the lungs were
only scored as radiation pneumonitis if they remained after the
use of antibiotics. In 60 out of 216 patients (27.8%), radiologic fea-
tures of radiation-induced pneumonitis were observed on follow
up CT scans. 3 patients experienced clinical symptoms requiring
steroids (grade 2), 6 of them were hospitalized (grade 3), another
4 patients eventually died of this complication (grade 5).
Univariate logistic regression analysis showed that most lung
dose parameters and some cardiac substructure dose parameters
were significantly associated with pneumonitis. Of the clinical fac-
tors, only diabetes mellitus (DM) was associated with this end-
point (suppl. Data Fig. 7). Multivariable logistic regression
analysis showed that radiation pneumonitis was best predicted
by the mean lung dose (MLD) only, with an odds ratio of 1.18
per Gy MLD (this model had an AUC of 0.67 (adjusted AUC after
bootstrapping = 0.63)).
Bootstrap analysis confirmed the robustness of the selection of
the MLD into the model. Calibration plots of the observed vs. calcu-
Table 1














Prescribed dose 60 Gy(50.4–66.0)
Elective irradiation 135(62.5%)
Chemotherapy 205(94.9%)
224 Can we safely reduce the radiation dose to the heart in oesophageal cancer patientslated risk of complications using the Hosmer-Lemeshow test
showed a good performance of the model as well (suppl. data
Figs. 1 and 2). In 69 out of 216 (31.9%) patients, pericardial effusion
(PE) was seen on the follow up CT scans. Nine of these patients
developed clinical symptoms of heart failure. Two other patients
presented with heart failure without signs of pericardial effusion.
They both had a cardiac history (1 valvular disease, 1 ischaemic
heart disease). Other cardiac events were diverse and are listed
in Table 3. The numbers of the separate toxicities were too low
for reliable modelling procedures. Combining clinical cardiac
events did not result in a predictive model. In univariate analysis,
most cardiac, but no lung, dose volume-parameters were related
to PE. None of the clinical factors were significantly associated with
PE (suppl. Data Fig. 8). In the multivariable analysis, PE was signif-
icantly associated with the volume of the RV receiving a dose
higher than 35 Gy (V35): OR = 1.03 (95%CI 1.017–1.039). This
model had an AUC of 0.73 (95% CI 0.66–0.80).
However, most dose volume parameters, including the mean
dose values of the WH, pericardium and RV, performed similarly
well in predicting PE (Table 4). Most of the heart parameters were
highly correlated so we eventually decided to present three models
for PE with the mean dose to the RV, the whole heart and to the
pericardium as explanatory variables, to facilitate a comparison
with results from the literature and use of the models in routine
daily practice. All models are presented in Table 4 and the model
using the mean pericardial dose is depicted in Fig. 1.Table 2
Clinical risk factors.
Parameter
Age at start treatment median
Seks female
male
WHO 0 vs 1 or higher 0
>0









* Any cardiac history, ischaemic event, rhythm disorders, heart failure, valve disorder
** Not taken into analysis because of too many missing values or low numbers per groThe bootstrap procedure and calibration curves again confirmed
the robust selection of dose volume parameters in the model
(suppl. data Figs. 3, 4); the adjusted AUC’s are included in Table 4.
With a median follow up of 27 months, 97 out of 216 patients
developed locoregional failures. The median disease-free survival
was 64 months (95% CI 58.7–69.3 months). The median OS was
not reached.
Univariable analysis showed that all lung as well as several car-
diac dose parameters were associated with OS. However the high
dose pulmonary DVH parameters performed significantly better
in predicting this endpoint (suppl. Data Fig. 9). Significant clinical
factors for worse OS were high tumour stage, highWHO-score, dia-
betes mellitus (DM), positive lymph nodes and the use of elective
radiotherapy. In the Cox-regression analysis, the V45 of the lungs,
DM and tumour stage remained significantly associated with OS.
The final model is presented in Table 4.
After the bootstrapping procedure, the same variables were
selected and included in the preferred model. The adjusted AUC
was 0.69 (suppl. Data Fig. 5).
Kaplan Meier analyses with regard to the effect of these toxici-
ties on OS showed a significantly worse OS for patients presenting
with radiation-induced pneumonitis (p = 0.013). Patients present-
ing with pericardial effusion had similar OS as compared to those
without pericardial effusion. All analyses are summarized in Fig. 2.
In order to get more insight in causal relationships between tox-
icity and OS, we reanalysed OS data censoring the patients having a
radiation pneumonitis. The same variables remained significant for
OS (Stage, DM and V45 lung). Performing the same analyses on
patients who developed radiation pneumonitis, the heart dose
(V55 heart) was the only predictor significantly predicting OS
(Suppl. Table 1).Discussion
In this paper, we aimed to identify clinical and/or dosimetric
parameters that are related to cardiac and/or pulmonary toxicity
in oesophageal cancer patients and analysed its effect on overall
survival. The total prescribed dose in this patient group was rela-
tively high which explains the OS compared favourable to the liter-
ature and the relatively high complication rates in this patient
group. This allowed us to develop a multivariable prediction model
for both heart and lung toxicity and report a comprehensive anal-
ysis of these toxicities in oesophageal cancer patients. Cardiac and
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Follow up and toxicity.
New pulmonary events
Radiation pneumonitis grade 1 47(22%)
Radiation pneumonitis grade 2 3(1%)
Radiation pneumonitis grade 3 6(3%)
Radiation pneumonitis grade 4 0(0%)
Radiation pneumonitis grade 5 4(2%)
New cardiac events
Pericardial effusion grade 2 60(28%)
Pericardial effusion grade 3 9(4%)
Angina pectoris any grade 3(1%)
Myocardial infarction any grade 4(2%)
Heart failure any grade 8(4%)
Arythmia any grade 8(4%)
Valvular disease any grade 1(0%)
Survival status at last FU
Alive, no evidence of disease 105(49%)
Alive with recurrent disease 33(15%)
Dead by index tumor 57(26%)
Dead by toxicity 5(2%)
Dead intercurrent disease 16(7%)
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should be based on the risk of toxicity of both organs at risk.
Regarding pulmonary toxicity, there is only limited data on the
risk of radiation pneumonitis in oesophageal cancer patients trea-
ted with definitive CRT. The published papers do not provide an
odds- or hazard ratio for radiation pneumonitis in this patient
group [20,21].
Our model on pericardial effusion is in line with other retro-
spective publications [7,22,23]. Dose response relationships with
different cardiac dose parameters were described in all of these
publications. Hayashi, et al. presented the odds ratios of several
cardiac DVH parameters related to PE. Our odds ratios seemed to
be slightly lower but remained within their 95% confidence inter-
vals [22]. Wei et al. analysed doses both to the pericardium and
whole heart and also found a stronger association for the pericar-
dial dose vs. mean heart dose on PCE, indeed suggesting a local
inflammatory effect [23].
To determine which toxicity is most relevant and consequently
which organ at risk should be prioritized in our planning strategies,
we finally focused on OS as an endpoint. In the multivariable anal-
ysis, we found that the dose to the lungs but not the radiation dose
to the heart influenced OS significantly in this patient population.
Moreover, the subgroup of patients with radiation pneumonitis
had a worse OS in Kaplan Meier analysis, as opposed to the patients
diagnosed with pericardial effusion, a side effect which did not
seem to influence OS. However, when repeating the survivalTable 4
NTCP models on toxicity endpoints using a logistic regression analysis and cox regression
Endpoint (logistic regression) Explanatory variable Intercept Odds rati
Radiation pneumonitis Mean dose lung 2.56 1.18
(Nagelkerke R2 = 0.08)
Pericardial effusion Mean dose pericard 3.26 1.11
(Nagelkerke R2 = 0.17)
Pericardial effusion Mean dose heart 3.11 1.09
(Nagelkerke R2 = 0.16)
Pericardial effusion Mean dose RV 3.24 1.08
(Nagelkerke R2 = 0.20)
Endpoint (cox regression) Explanatory variable Hazard R
Overall Survival (Cox regression) V 45 Lung 1.23
Stage I and II vs Stage III and IV 2.34
Diabetes 0.33analyses censoring patients with a RP, the same variables remained
significant for OS, suggesting the clinical diagnosis of radiation
pneumonitis itself might not be the cause for worse OS. In the
patient group presenting with radiation pneumonitis, we found
the heart dose the most important predictor for OS.
These findings suggest that worse OS can be caused by radiation
dose to both organs at risk, but the biological mechanism remains
unknown. Given the prognostic significance of a heart dose param-
eter in the radiation pneumonitis patient group, and not in the
whole group, a possible explanation can be found in the physiolog-
ical interaction of the heart and lungs.
In preclinical studies, this interaction between heart and lung
irradiation was objectified. Combining radiation on heart and lungs
resulted in a synergistic effect on cardiopulmonary toxicity in rats.
On pathologic examinations this interaction seemed to be caused
by small vascular damage in lung tissue and perivascular fibrosis
in heart tissue, resulting in pulmonary hypertension and reduced
diastolic function [24,25].
Clinically, worse OS rates after (higher dose) thoracic radiother-
apy despite better local control also suggests underreported toxic-
ity, perhaps even unrecognized toxicity [10,24]. In several (SEER)
database studies, higher cardiac death rates were reported in distal
tumours and with the use of ‘‘older radiotherapy techniques” sug-
gesting radiation induced toxicity of the heart [12,25–27]. More
recent publications, like ours, are able to present DVH data on dif-
ferent critical organs and its relation to overall survival. Although
several papers have been published on the correlation of cardiac
dose with OS, there are reasons to be cautious of increasing the
dose to the lungs in an attempt to spare the heart. The correlations
found with cardiac dose in the literature might have been a reflec-
tion of the absence of cardiac toxicity models while lung toxicity
models have been available for a longer period of time, resulting
in strict planning criteria for the V20 of the lungs and the mean
lung dose. Furthermore, in several of the earlier mentioned trials,
not only the dose to the heart but total dose to the lungs was pre-
dictive for OS as well [11,16,28–30].
Altogether it is important to consider both heart and lungs as
organs at risk in the treatment of thoracic indications. Especially
in VMAT or IMRT techniques, cardiac dose reduction will be at
the expense of a higher lung dose. Proton therapy on the other
hand can reduce both the radiation dose to the heart and lungs.
In a recent trial randomizing between photon and proton CRT, a
significant reduction of treatment related complications was seen;
the total toxicity score was 2.3 times lower after proton radiother-
apy, compared to IMRT treated patients [31]. Therefore, it is
preferable to combine both heart and lung DVH parameters in
these prediction models. These models should originate frommodels on overall survival.
o CI (95%) Significance Performance Adjusted AUC
[1.07–1.30] 0.00
AUC 0.67 [0.58–0.75] 0.63
[1.06–1.16] 0.00
AUC 0.73 [0.66–0.80] 0.70
[1.05–1.12] 0.00
AUC 0.72 [0.65–0.79] 0.69
[1.05–1.11] 0.00
AUC 0.73 [0.67–0.80] 0.71




AUC 0.73 [0.67–0.80] AUC 0.70
Fig. 1. NTCP curves on radiation induced pulmonary and cardiac toxicities.
Fig. 2. Overview of the performed analyses and its relationships and predictive
factors (Vmean RV = mean dose on the right ventricle, MLD = mean lung dose,
DM = diabetes Mellitus).
226 Can we safely reduce the radiation dose to the heart in oesophageal cancer patientsprospective data and be validated in independent cohorts to be
robust against institutional differences. A further understanding
of the mechanisms behind these toxicities can facilitate the devel-
opment of these models and make them more robust in different
patient groups by not only selecting the best performing variables
in that cohort of patients but including the most (clinically) rele-
vant parameters [32]. Besides this, more knowledge in mecha-
nisms will help in early detection and preventive measurements
in these patient groups.
We did not find a convincing explanation for the better survival
of diabetic patients in this multivariable model. The difference in
overall survival in these diabetic patients in univariate analysis
became apparent after 20 months, suggesting it was not tumour
related but might be patient or therapy related as the highest risk
for tumour recurrence is within the first two years (Fig. 7, suppl.
data). Diabetic patients had a significantly higher dose to the lungs
and experienced radiation pneumonitis more frequently but, in
these patients, it did not seem to influence overall survival as much
as it did in the non-diabetic patients. A possible explanation might
be a stricter follow up in these patients in which more preventive
measurements might have been taken. A stricter patient selection
for the curative treatment schedule might be another explanation.
Summarizing, cardiac dose volume parameters predicted the
risk of pericardial effusion and pulmonary dose volume parameters
predicted the risk of radiation pneumonitis. However, in this
patient cohort, pulmonary DVH parameters (V45) were more
important for OS than cardiac DVH parameters. These results sug-
gest that reducing the cardiac dose at the expense of the dose tothe lungs might not always be a good strategy in oesophageal can-
cer patients.
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